ORBUSNEICH's research and production base in Hangzhou has topped out

ORBUSNEICH (06929.HK) announced that its research and production base located in Fuyang, Hangzhou, completed structural topping yesterday (16th), becoming the company's largest integrated research and production facility globally. It is expected to obtain all relevant licenses by 2027 and commence full production, at which point ORBUSNEICH's total annual production capacity will increase by approximately 2.4 million products annually, based on the current capacity of about 2.1 million balloons and stents.

The Hangzhou base covers an area of approximately 20,000 square meters, with a building area of nearly 60,000 square meters, focusing on the research and production of PCI and PTA interventional products, as well as structural heart disease devices. The total investment in the project is approximately 430 million RMB, equipped with automated production lines to reduce labor costs.

The group expects that the establishment of the Hangzhou base will significantly enhance high-quality production capacity, accelerate the incubation and application of new technologies, strengthen the stability of the global supply chain and overall competitiveness, and help seize the opportunities presented by the continuous growth of the global PCI and PTA device market